BMS-202
BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma cells. In addition, BMS-202 has an inhibitory effect on both PD-L1-expressing cancer cells and activated T cells.